GlassScriptPhysician profile
Andrew W Johnson
NPI 1730778978
$22,371.97
in general payments reported to CMS, 2019-2025
36 companies · $4,545 in 2025
The $4,545 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,779 · 2022: $5,038 · 2023: $5,890 · 2024: $5,120 · 2025: $4,545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,555.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,611.73 | 2021-2025 | Caplyta |
| Abbvie INC. | $2,147.87 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $2,091.65 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $1,991.04 | 2021-2025 | Austedo Xr, Austedo, Uzedy |
| Otsuka America Pharmaceutical, INC. | $1,831.64 | 2021-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Vanda Pharmaceuticals INC. | $1,752.22 | 2021-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $1,738.64 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $957.44 | 2021-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $939.21 | 2021-2025 | Rexulti |
| Noven Therapeutics, LLC | $603.30 | 2021-2025 | Xelstrym |
| Takeda Pharmaceuticals U.S.A., INC. | $565.29 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $465.04 | 2022-2025 | Auvelity, Sunosi |
| Idorsia Pharmaceuticals US INC | $460.94 | 2022-2025 | Quviviq, Quviviq |
| Indivior INC. | $456.63 | 2022-2025 | Perseris, Sublocade |
| E.R. Squibb & Sons, L.L.C. | $420.82 | 2024-2025 | Cobenfy |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $407.13 | 2021-2022 | |
| Corium, LLC | $371.80 | 2023-2024 | Azstarys |
| Uswm, LLC | $343.91 | 2021-2024 | Lucemyra, Zimhi |
| Boston Scientific Corporation | $332.49 | 2021-2023 | Synergy, Opticross |
| Bausch Health US, LLC | $308.99 | 2021-2025 | Aplenzin, Wellbutrin |
| Biogen, INC. | $252.62 | 2022-2025 | Zurzuvae |
| Supernus Pharmaceuticals, INC. | $244.88 | 2023-2025 | Qelbree |
| Avanir Pharmaceuticals, INC. | $222.74 | 2021-2022 | |
| Almatica Pharma LLC | $200.67 | 2021-2024 | Loreev Xr, Sertraline Hcl |
| Neuronetics, INC. | $189.68 | 2022 | |
| Ironshore Pharmaceuticals INC. | $71.16 | 2023-2024 | Jornay Pm |
| Braeburn INC. | $66.95 | 2025 | Brixadi |
| Avadel Cns Pharmaceuticals, LLC | $61.13 | 2025 | Lumryz |
| Merck Sharp & Dohme LLC | $54.86 | 2021-2023 | Belsomra |
| Tris Pharma INC | $50.49 | 2024-2025 | Dyanavel Xr |
| Owp Pharmaceuticals, INC. | $43.91 | 2022-2024 | Subvenite |
| Avion Pharmaceuticals | $35.36 | 2023 | Methylphenidate Hydrochloride |
| Livanova USA, INC. | $23.47 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
| Adlon Therapeutics L.P. | $23.01 | 2021 | |
| Sumitomo Pharma America, INC. | $17.70 | 2023 | Latuda |
| Lilly USA, LLC | $15.56 | 2024 | Amyvid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.